在接受ChAdOx1- S治疗的参与者中,BNT162b2增强剂的免疫性和反应性 (CombiVacS):多中心,开放,随机,受控的第二阶段试验
Alberto M Borobia1, Antonio J Carcas1, Mayte Pérez-Olmeda2
1Servicio de Farmacología Clínica, Departamento de Farmacología y Terapéutica, Facultad de Medicina, Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, Madrid, Spain.
Lancet (London, England)
|June 28, 2021
概括
在ChAdOx1- S疫苗 (Vaxzevria) 之后,第二剂BNT162b2疫苗 (Comirnaty) 在成年人中产生了强烈的免疫反应. 这种异种疫苗接种方案显示出可接受的安全性,并有轻度至中度的副作用.
科学领域:
- 免疫学
- 疫苗学
- 公共卫生
背景情况:
- 对于人类的COVID-19异种疫苗接种计划,免疫学数据有限.
- 这项研究涉及BNT162b2第二剂的免疫性和反应性.
研究的目的:
- 评估使用BNT162b2作为第二剂COVID-19疫苗的免疫反应和副作用.
- 提供关于异种疫苗计划的关键数据.
主要方法:
- 这是一项2期,开放性,随机对照试验,涉及18至60岁的676名成年人.
- 参与者在一次ChAdOx1- S剂量后8-12周接受了BNT162b2的第二剂量.
- 通过尖端蛋白和RBD抗体标位,中和试验和细胞免疫反应评估免疫性;通过不良事件评估安全性.
主要成果:
- 在BNT162b2接种疫苗后的14天内,RBD和三元蛋白IgG抗体标位显著增加.
- 与对照组相比,发现抗体增加的比例很高.
- 大多数报告的不良反应为轻度至中度,包括注射部位疼痛,头痛和肌痛,没有严重的不良反应.
结论:
- 在ChAdOx1- S初始注射后的第二剂BNT162b2诱导强烈的免疫反应.
- 异种疫苗接种方案显示了可接受和可控的反应性.
相关概念视频
Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
556
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
556
Bioavailability Study Design: Single Versus Multiple Dose Studies
339
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
339
Bioavailability Study Design: Healthy Subjects Versus Patients
213
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
213
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
375
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
375
Bioequivalence studies: Biowaivers
401
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
401


